Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 443

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Open access
Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Kaufman, Jonathan L., Ifthikharuddin, Jainulabdeen J., Weiss, Brendan M., Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Raymond, Wang, Jianping, Nottage, Kerri, Chiu, Christopher, Khokhar, Nushmia Z., Ahmadi, Tahamtan, Lonial, Sagar·2017·Blood

Abstract

Key Points: No new safety signals were observed with daratumumab plus pomalidomide and dexamethasone, except for increased neutropenia. Daratumumab plus pomalidomide and dexamethasone induced rapid, deep, and durable responses in heavily treated patients with multiple myeloma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2017-05-785246

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 2

  1. Richardson, 2016, Preliminary results from a phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma [abstract], 10.1182/blood.V128.22.2123.2123 · doi:10.1182/blood.v128.22.2123.2123
  2. Richardson, 2013, MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM), J Clin Oncol, 31, 8584, 10.1200/jco.2013.31.15_suppl.8584 · doi:10.1200/jco.2013.31.15_suppl.8584

Cited by

See all 443

Metadata

Authors
Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A., Lentzsch, S., Comenzo, R., Wang, J., Nottage, K., Chiu, C., Khokhar, N. Z., Ahmadi, T., & Lonial, S.
Venue
Blood
Published
2017-08-24
Volume
130
Issue
8
Pages
974-981
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2688500010
Cited by
443
References
23
FWCI
44.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2017-05-785246
The paper
Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A., Lentzsch, S., Comenzo, R., Wang, J., Nottage, K., Chiu, C., Khokhar, N. Z., Ahmadi, T., & Lonial, S. (2017). Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2017-05-785246

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.